
Opinion|Videos|March 10, 2025
Molecular Monitoring Advances in PV Disease Assessment and Management
Author(s)Prithviraj Bose, MD
A panelist discusses how advances in JAK2 V617F and other molecular monitoring have enhanced their ability to assess polycythemia vera (PV) disease progression and guide initial treatment decisions by providing quantifiable markers for tracking mutation burden, treatment response, and risk stratification that complement traditional clinical parameters.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Please explain how advances in JAK2 V617Fand other molecular monitoring have enhanced your ability to assess disease progression and guide initial treatment decisions for your patients with PV.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Ropeginterferon Alfa Gains NCCN Backing in Essential Thrombycythemia
2
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
3
BI-1808 Plus Pembrolizumab Yield Antitumor Activity in Recurrent Ovarian Cancer
4
NCCN Updates Breast Cancer Guidelines: Sacituzumab Govitecan for 1L TNBC
5



















